Jonathan Farhi

576 total citations
14 papers, 135 citations indexed

About

Jonathan Farhi is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Jonathan Farhi has authored 14 papers receiving a total of 135 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 6 papers in Genetics and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Jonathan Farhi's work include Acute Myeloid Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Jonathan Farhi is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Jonathan Farhi collaborates with scholars based in France and United States. Jonathan Farhi's co-authors include Kamel Laribi, Alix Baugier de Materre, Jérémy Sandrini, Pierre Lemaire, Mélanie Mercier, Corentin Orvain, Mathilde Hunault, Aline Schmidt, Jean‐François Hamel and Norbert Ifrah and has published in prestigious journals such as Blood, Transplantation and Cancers.

In The Last Decade

Jonathan Farhi

12 papers receiving 132 citations

Peers

Jonathan Farhi

PFM

ONCOL

GENET

HEMAT

NEURO

Candice Del Rio United States

Jun Amaki Japan

Yoshiaki Usui Japan

Andrés JM Ferreri Italy

Mansoor Noorani United States

Christina Howlett United States

Anne Lazareth France

Gayane Tumyan Russia

Tetiana Skrypets Italy

Zhiming Li China

Candice Del Rio United States

Jonathan Farhi

59 ×0.9

PFM

33 ×0.5

ONCOL

36 ×0.8

GENET

43 ×1.2

HEMAT

38 ×1.1

NEURO

Citations per year, relative to Jonathan Farhi Jonathan Farhi (= 1×) peers Candice Del Rio

Countries citing papers authored by Jonathan Farhi

Since Specialization

Citations

This map shows the geographic impact of Jonathan Farhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Farhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Farhi more than expected).

Fields of papers citing papers by Jonathan Farhi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Farhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Farhi. The network helps show where Jonathan Farhi may publish in the future.

Co-authorship network of co-authors of Jonathan Farhi

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Farhi. A scholar is included among the top collaborators of Jonathan Farhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Farhi. Jonathan Farhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Rennke, Helmut G., Marie Essig, Martin Carré, et al.. (2023). Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease. Kidney International Reports. 8(12). 2733–2741. 2 indexed citations

Mercier, Mélanie, Corentin Orvain, Laurianne Drieu La Rochelle, et al.. (2021). Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement. Cancers. 13(12). 2945–2945.

Lacout, Carole, Corentin Orvain, Valérie Seegers, et al.. (2020). R‐DHA‐oxaliplatin (R‐DHAOx) versus R‐DHA‐cisplatin (R‐DHAP) regimen in B‐cell lymphoma treatment: A eight‐year trajectory study. European Journal Of Haematology. 105(2). 223–230.

Laribi, Kamel, et al.. (2019). Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine. Cancer Medicine. 8(5). 2188–2195. 5 indexed citations

Laribi, Kamel, et al.. (2018). Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine. Experimental Hematology. 65. 34–37. 6 indexed citations

Orvain, Corentin, François Beloncle, Jean‐François Hamel, et al.. (2018). Allogeneic stem cell transplantation recipients requiring intensive care: time is of the essence. Annals of Hematology. 97(9). 1601–1609. 8 indexed citations

Farhi, Jonathan, Kamel Laribi, Corentin Orvain, et al.. (2018). Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma. Annals of Hematology. 97(12). 2391–2401. 14 indexed citations

Orvain, Corentin, Damien Luque Paz, Irène Dobo, et al.. (2016). Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Annals of Hematology. 95(11). 1819–1823. 6 indexed citations

Laribi, Kamel, et al.. (2016). Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies. Biology of Blood and Marrow Transplantation. 22(8). 1357–1367. 37 indexed citations

10.

Orvain, Corentin, François Beloncle, Jean‐François Hamel, et al.. (2016). Different Impact of the Number of Organ Failures and Graft-Versus-Host Disease on the Outcome of Allogeneic Stem Cell Transplantation Recipients Requiring Intensive Care. Transplantation. 101(2). 437–444. 9 indexed citations

11.

Laribi, Kamel, et al.. (2016). R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Annals of Hematology. 95(10). 1705–1714. 31 indexed citations

12.

Laribi, Kamel, Jonathan Farhi, Pierre Lemaire, et al.. (2016). The bendamustine plus rituximab regimen is active against primary nodal marginal zone B‐cell lymphoma. Hematological Oncology. 35(4). 536–541. 14 indexed citations

13.

Danu, Alina, Sophie Cotteret, Ludovic Lacroix, et al.. (2016). BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening. Blood. 128(22). 5638–5638. 2 indexed citations

14.

Lacout, Carole, Aline Clavert, Jonathan Farhi, et al.. (2015). R-DHA-Oxaliplatin Versus R-DHA-Cisplatin Regimen in B-Cell Nhl's Treatment: A Eight Years Retrospective Study. Blood. 126(23). 3959–3959. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact